Home › Companies › CULLINAN THERAPEUTICS INC. › 2024-2025
Compiled from SEC Form N-PX filings and CULLINAN THERAPEUTICS INC.’s Form 8-K, filed June 12, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of June 12, 2025: 5 items on CULLINAN THERAPEUTICS INC.’s Form 8-K, filed June 12, 2025: 2 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore CULLINAN THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are CULLINAN THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Anthony Rosenberg | 47,044,236 | -- | -- | 1,926,370 | 3,138,175 | 96% | Not verified | — |
| Elect Director: David P. Ryan, M.D. | 47,241,434 | -- | -- | 1,729,172 | 3,138,175 | 96% | Not verified | — |
| Elect Director: Mary Thistle | 48,835,369 | -- | -- | 135,237 | 3,138,175 | 99.7% | Not verified | — |
| 2. Ratification of Appointment of Independent Registered Accounting Firm | 51,936,984 | 157,477 | 14,320 | -- | 0 | 99.6% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 46,956,042 | 1,999,889 | 14,675 | -- | 3,138,175 | 96% | Approved | — |
Source: CULLINAN THERAPEUTICS INC., Form 8-K, filed with the SEC on June 12, 2025 — read the filing on EDGAR.
Each item below shows how the 156 asset managers that disclosed a CULLINAN THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CULLINAN THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2028: Anthony Rosenberg
CULLINAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Anthony Rosenberg”): 47,044,236 for, 1,926,370 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 8,303,280 for, 1,189,443 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,954,348 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,268,994 | 0 | 0 | 0 | For |
| BlackRock | 1,224,102 | 0 | 0 | 0 | For |
| Fidelity | 1,123,715 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 950,416 | Withhold |
| Charles Schwab | 427,114 | 0 | 0 | 0 | For |
| State Street | 260,622 | 0 | 0 | 0 | For |
| Dimensional | 201,261 | 0 | 0 | 0 | For |
| TIAA | 187,390 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 175,879 | Withhold |
| Equitable | 91,445 | 0 | 0 | 44,060 | Mixed |
| American Century | 115,514 | 0 | 0 | 0 | For |
| Lincoln Financial | 73,344 | 0 | 0 | 0 | For |
| Northern Trust | 42,862 | 0 | 0 | 0 | For |
| Tema ETF Trust | 39,605 | 0 | 0 | 0 | For |
| Brighthouse | 19,002 | 0 | 0 | 13,848 | Mixed |
| Global X | 30,183 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 26,697 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 25,103 | 0 | 0 | 0 | For |
| ProShares | 22,904 | 0 | 0 | 0 | For |
| John Hancock | 20,934 | 0 | 0 | 0 | For |
| Pacific Life | 17,335 | 0 | 0 | 0 | For |
| Voya | 14,397 | 0 | 0 | 0 | For |
| ETF Series Solutions | 14,107 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,084 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2028: David P. Ryan, M.D.
CULLINAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: David P. Ryan, M.D.”): 47,241,434 for, 1,729,172 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 8,308,520 for, 1,184,203 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,954,348 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,268,994 | 0 | 0 | 0 | For |
| BlackRock | 1,224,102 | 0 | 0 | 0 | For |
| Fidelity | 1,123,715 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 950,416 | Withhold |
| Charles Schwab | 427,114 | 0 | 0 | 0 | For |
| State Street | 260,622 | 0 | 0 | 0 | For |
| Dimensional | 201,261 | 0 | 0 | 0 | For |
| TIAA | 187,390 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 175,879 | Withhold |
| Equitable | 91,445 | 0 | 0 | 44,060 | Mixed |
| American Century | 115,514 | 0 | 0 | 0 | For |
| Lincoln Financial | 73,344 | 0 | 0 | 0 | For |
| Northern Trust | 42,862 | 0 | 0 | 0 | For |
| Tema ETF Trust | 39,605 | 0 | 0 | 0 | For |
| Brighthouse | 19,002 | 0 | 0 | 13,848 | Mixed |
| Global X | 30,183 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 26,697 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 25,103 | 0 | 0 | 0 | For |
| ProShares | 22,904 | 0 | 0 | 0 | For |
| John Hancock | 20,934 | 0 | 0 | 0 | For |
| Pacific Life | 17,335 | 0 | 0 | 0 | For |
| Voya | 14,397 | 0 | 0 | 0 | For |
| ETF Series Solutions | 14,107 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,084 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2028: Mary Thistle
CULLINAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mary Thistle”): 48,835,369 for, 135,237 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 9,478,875 for, 13,848 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,954,348 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,268,994 | 0 | 0 | 0 | For |
| BlackRock | 1,224,102 | 0 | 0 | 0 | For |
| Fidelity | 1,123,715 | 0 | 0 | 0 | For |
| AllianceBernstein | 950,416 | 0 | 0 | 0 | For |
| Charles Schwab | 427,114 | 0 | 0 | 0 | For |
| State Street | 260,622 | 0 | 0 | 0 | For |
| Dimensional | 201,261 | 0 | 0 | 0 | For |
| TIAA | 187,390 | 0 | 0 | 0 | For |
| Principal | 175,879 | 0 | 0 | 0 | For |
| Equitable | 135,505 | 0 | 0 | 0 | For |
| American Century | 115,514 | 0 | 0 | 0 | For |
| Lincoln Financial | 73,344 | 0 | 0 | 0 | For |
| Northern Trust | 42,862 | 0 | 0 | 0 | For |
| Tema ETF Trust | 39,605 | 0 | 0 | 0 | For |
| Brighthouse | 19,002 | 0 | 0 | 13,848 | Mixed |
| Global X | 30,183 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 26,697 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 25,103 | 0 | 0 | 0 | For |
| ProShares | 22,904 | 0 | 0 | 0 | For |
| John Hancock | 20,934 | 0 | 0 | 0 | For |
| Pacific Life | 17,335 | 0 | 0 | 0 | For |
| Voya | 14,397 | 0 | 0 | 0 | For |
| ETF Series Solutions | 14,107 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,084 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
Combines 6 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.
CULLINAN THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 46,956,042 for, 1,999,889 against — passed, per its Form 8-K filed June 12, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Three — Advisory Vote on Executive Compensation The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers by the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,954,348 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,268,994 | 0 | 0 | 0 | For |
| BlackRock | 1,224,102 | 0 | 0 | 0 | For |
| Fidelity | 1,123,715 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 950,416 | 0 | 0 | Against |
| Charles Schwab | 427,114 | 0 | 0 | 0 | For |
| State Street | 260,552 | 70 | 0 | 0 | For |
| Dimensional | 201,261 | 0 | 0 | 0 | For |
| TIAA | 187,390 | 0 | 0 | 0 | For |
| Principal | 0 | 175,879 | 0 | 0 | Against |
| Equitable | 91,445 | 44,060 | 0 | 0 | Mixed |
| American Century | 0 | 115,514 | 0 | 0 | Against |
| Lincoln Financial | 73,344 | 0 | 0 | 0 | For |
| Northern Trust | 42,862 | 0 | 0 | 0 | For |
| Tema ETF Trust | 39,605 | 0 | 0 | 0 | For |
| Brighthouse | 19,002 | 0 | 13,848 | 0 | Mixed |
| Global X | 30,183 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 26,697 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 25,103 | 0 | 0 | 0 | For |
| ProShares | 22,904 | 0 | 0 | 0 | For |
| John Hancock | 20,934 | 0 | 0 | 0 | For |
| Pacific Life | 17,335 | 0 | 0 | 0 | For |
| Voya | 14,397 | 0 | 0 | 0 | For |
| ETF Series Solutions | 14,107 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,084 | 0 | 0 | 0 | For |
Fund voting reports, all 47 managers: 8,186,423 for, 1,292,452 against, 13,848 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MPM BioImpact LLC | 7,648,268 | 0 | 0 | 0 | For |
| BVF INC/IL | 5,750,683 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3,650,893 | 0 | 0 | 0 | For |
| Lynx1 Capital Management LP | 3,339,816 | 0 | 0 | 0 | For |
| Blue Owl Capital Holdings LP | 2,435,948 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 2,180,871 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 1,923,855 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 1,705,960 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 1,599,875 | 0 | 0 | Against |
| BlackRock | 1,412,687 | 10,124 | 0 | 0 | For |
| Kynam Capital Management, LP | 0 | 0 | 0 | 1,417,426 | Withhold |
| VR Adviser, LLC | 1,379,965 | 0 | 0 | 0 | For |
| Citadel | 1,301,496 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,246,282 | 0 | 0 | 0 | For |
| State Street | 1,229,522 | 281 | 0 | 0 | For |
| Siren, L.L.C. | 1,044,094 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 834,651 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 644,633 | 0 | 0 | 0 | For |
| Foresite Capital Management VI LLC | 634,558 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 575,712 | 0 | 0 | 0 | For |
| Charles Schwab | 441,908 | 0 | 0 | 0 | For |
| Northern Trust | 261,556 | 0 | 0 | 0 | For |
| Nuveen | 188,030 | 0 | 0 | 0 | For |
| Dimensional | 171,164 | 0 | 0 | 0 | For |
| Voss Capital, LP | 155,351 | 0 | 0 | 0 | For |
Institutional-manager reports, all 127 managers: 41,202,542 for, 1,826,216 against, 1,417,426 withheld, 14,578 1 year. Showing the 25 largest; see all in the interactive database.
Combines 4 wordings of this item as funds reported it.
65% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: PROPOSAL TO VOTE, ON AN ADVISORY BASIS, ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON OUR NAMED EXECUTIVE OFFICER COMPENSATION.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| Principal | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 30,704 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Tema ETF Trust | 0 | 0 | 0 | 0 | -- |
| Brighthouse | 0 | 0 | 13,848 | 0 | Abstain |
| Global X | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 0 | -- |
| ProShares | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| Pacific Life | 0 | 0 | 0 | 0 | -- |
| Voya | 0 | 0 | 0 | 0 | -- |
| ETF Series Solutions | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 47 managers: 30,704 for, 13,848 abstained, 9,222,453 1 year, 225,718 3 year. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MPM BioImpact LLC | 0 | 0 | 0 | 0 | -- |
| BVF INC/IL | 0 | 0 | 0 | 0 | -- |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 0 | 0 | 0 | 0 | -- |
| Lynx1 Capital Management LP | 0 | 0 | 0 | 0 | -- |
| Blue Owl Capital Holdings LP | 2,435,948 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 0 | 0 | 0 | 0 | -- |
| ORBIMED ADVISORS LLC | 0 | 0 | 0 | 0 | -- |
| RTW INVESTMENTS, LP | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Kynam Capital Management, LP | 0 | 0 | 0 | 1,417,426 | Withhold |
| VR Adviser, LLC | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Siren, L.L.C. | 0 | 0 | 0 | 0 | -- |
| BRAIDWELL LP | 0 | 0 | 0 | 0 | -- |
| Rock Springs Capital Management LP | 0 | 0 | 0 | 0 | -- |
| Foresite Capital Management VI LLC | 0 | 0 | 0 | 0 | -- |
| MARSHALL WACE, LLP | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Nuveen | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| Voss Capital, LP | 155,351 | 0 | 0 | 0 | For |
Institutional-manager reports, all 123 managers: 2,607,975 for, 20 against, 1,417,426 withheld, 40,201,175 1 year, 171,164 3 year. Showing the 25 largest; see all in the interactive database.
99.6% Approved · of votes cast
Description as filed by funds: Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2025.
CULLINAN THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Accounting Firm”): 51,936,984 for, 157,477 against — passed, per its Form 8-K filed June 12, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Two — Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025 by the following votes:”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 9,478,765 for, 110 against, 13,848 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,954,348 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,268,994 | 0 | 0 | 0 | For |
| BlackRock | 1,224,102 | 0 | 0 | 0 | For |
| Fidelity | 1,123,715 | 0 | 0 | 0 | For |
| AllianceBernstein | 950,416 | 0 | 0 | 0 | For |
| Charles Schwab | 427,114 | 0 | 0 | 0 | For |
| State Street | 260,622 | 0 | 0 | 0 | For |
| Dimensional | 201,261 | 0 | 0 | 0 | For |
| TIAA | 187,390 | 0 | 0 | 0 | For |
| Principal | 175,879 | 0 | 0 | 0 | For |
| Equitable | 135,505 | 0 | 0 | 0 | For |
| American Century | 115,514 | 0 | 0 | 0 | For |
| Lincoln Financial | 73,344 | 0 | 0 | 0 | For |
| Northern Trust | 42,862 | 0 | 0 | 0 | For |
| Tema ETF Trust | 39,605 | 0 | 0 | 0 | For |
| Brighthouse | 19,002 | 0 | 13,848 | 0 | Mixed |
| Global X | 30,183 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 26,697 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 25,103 | 0 | 0 | 0 | For |
| ProShares | 22,904 | 0 | 0 | 0 | For |
| John Hancock | 20,934 | 0 | 0 | 0 | For |
| Pacific Life | 17,335 | 0 | 0 | 0 | For |
| Voya | 14,397 | 0 | 0 | 0 | For |
| ETF Series Solutions | 14,107 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,084 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 58,698,919 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.03% |
| 2 | FRANKLIN STRATEGIC SERIES | 2.16% |
| 3 | BlackRock | 2.09% |
| 4 | Fidelity | 1.91% |
| 5 | AllianceBernstein | 1.62% |
| 6 | Charles Schwab | 0.73% |
| 7 | State Street | 0.44% |
| 8 | Dimensional | 0.34% |
| 9 | TIAA | 0.32% |
| 10 | Principal | 0.30% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | MPM BioImpact LLC | 13.03% |
| 2 | BVF INC/IL | 9.80% |
| 3 | DEERFIELD MANAGEMENT COMPANY, L.P. | 6.22% |
| 4 | Lynx1 Capital Management LP | 5.69% |
| 5 | Blue Owl Capital Holdings LP | 4.15% |
| 6 | FRANKLIN ADVISERS INC | 3.72% |
| 7 | ORBIMED ADVISORS LLC | 3.28% |
| 8 | RTW INVESTMENTS, LP | 2.91% |
| 9 | AllianceBernstein | 2.73% |
| 10 | BlackRock | 2.42% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BVF PARTNERS L P/IL | 10.50% | 13G |
| LYNX1 CAPITAL MANAGEMENT LP | 9.82% | 13G |
| BlackRock | 7.19% | 13F |
| Vanguard Group | 5.18% | 13F |
| Deerfield Mgmt, L.P. | 4.99% | 13G |
| Citadel Advisors | 4.72% | 13F |
| Franklin Templeton | 3.78% | 13F |
| Kenneth Griffin | 3.39% | 13G |
| State Street | 2.99% | 13F |
| Dimensional Fund Advisors | 2.22% | 13F |
Percentages above are of 58,698,919 shares outstanding, as reported by CULLINAN THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CULLINAN THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At CULLINAN THERAPEUTICS INC.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 156 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,226 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION. — CULLINAN THERAPEUTICS INC.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CULLINAN THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2025.
CULLINAN THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.